An investigational glucagon-receptor / GLP-1-receptor dual agonist studied for weight loss and for MASH (fatty liver disease). It is not FDA-approved.
Reviewed for accuracy · Last reviewed July 8, 2026Survodutide (development code BI 456906) activates two metabolic receptors at once: GLP-1 and glucagon. The GLP-1 arm is shared with drugs like semaglutide and helps curb appetite, while the glucagon arm is proposed to add direct effects on liver fat and energy expenditure. That dual action is why it has been studied both for weight loss and for MASH (metabolic dysfunction-associated steatohepatitis).
It is given as a once-weekly subcutaneous injection, starting low and escalating over several weeks. Survodutide is investigational: it is being developed by Boehringer Ingelheim (licensed from Zealand Pharma) and is not approved by the FDA for any use, so the figures here describe what trials tested rather than an approved regimen.
The Phase 2 obesity trial escalated once-weekly subcutaneous survodutide from 0.6 mg up to a 4.8 mg maintenance dose over 46 weeks. It is investigational, so there is no approved prescribing dose.
Read the full Survodutide dosage guide →Across trials the most common adverse events were gastrointestinal (nausea, vomiting, diarrhea, constipation), generally dose-related and most prominent during escalation.
Read the full Survodutide side effects guide →Keep unmixed material refrigerated and away from light. Because survodutide is investigational, there is no consumer storage label; general peptide handling applies. See the full storage & safety guide for handling and disposal basics.
This page is an independent educational reference and is not medical advice, and does not indicate any approval status for any use. Survodutide is investigational. Talk to a doctor before starting any compound.